Lead Product(s) : Memantine Hydrochloride,Donepezil
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Amneal Receives FDA Approval for Memantine/Donepezil and Tentative Approval for Rifaximin
Details : A generic combination of memantine HCl extended-release, a NMDA receptor antagonist, and donepezil HCl, an acetylcholinesterase inhibitor, is approved for dementia of the Alzheimer’s.
Product Name : Namzaric
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 23, 2025
Lead Product(s) : Memantine Hydrochloride,Donepezil
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ADLARITY (donepezil transdermal system) developed by Corium, is the first and only U.S. FDA approved once-weekly, donepezil transdermal system for patients with mild, moderate and severe dementia of the Alzheimer's type.
Product Name : Adlarity
Product Type : Small molecule
Upfront Cash : Not Applicable
September 12, 2023
Details : Under the terms of the agreement, Lotus will have exclusive rights to commercialize Adlarity (donepezil transdermal system), an innovative Alzheimer’s dementia treatment, in the applicable territory and will be responsible for the regulatory approval p...
Product Name : Adlarity
Product Type : Small molecule
Upfront Cash : Undisclosed
August 10, 2023
Lead Product(s) : Masupirdine,Donepezil,Memantine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Suven Life Sciences Breathes New Life Into Drug Discovery Plans
Details : SUVN-502 (masupirdine) is a novel, potent, pure, and orally active 5-HT6 receptor antagonist, it is being investigated as a potential therapy against alzheimer's disease.
Product Name : SUVN-502
Product Type : Small molecule
Upfront Cash : Not Applicable
March 11, 2023
Lead Product(s) : Masupirdine,Donepezil,Memantine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Donepezil,Memantine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
NeuroSense Therapeutics Reports Positive Final Results from Alzheimer's Biomarker Study
Details : Cognic (donepezil) is a transactive response DNA binding protein of 43 kDa (TDP-43) is involved in regulation of gene expression. AD patients with TDP-43 pathology have increased severity of cognitive impairment compared to those without TDP-43 pathology...
Product Name : Cognic
Product Type : Small molecule
Upfront Cash : Not Applicable
January 19, 2023
Lead Product(s) : Donepezil,Memantine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The results of Study 419 did not show statistically significant difference in efficacy between placebo and Aricept (donepezil hydrochloride) groups at time of final analysis in primary endpoint, CIBIC-plus comprehensive assessment.
Product Name : Aricept
Product Type : Small molecule
Upfront Cash : Not Applicable
November 29, 2022
Details : ADLARITY is the first and only once-weekly patch to continuously deliver consistent doses of donepezil through the skin. Donepezil is the most prescribed medication in a class of Alzheimer's drugs known as acetylcholinesterase inhibitors.
Product Name : Adlarity
Product Type : Small molecule
Upfront Cash : Not Applicable
September 19, 2022
Details : KemPharm is due to receive the fee, within 30 days following FDA approval of ADLARITY, pursuant to a master development services agreement entered into with Corium in July 2020, under which KemPharm provided development related to Corium’s resubmission...
Product Name : Adlarity
Product Type : Small molecule
Upfront Cash : Undisclosed
March 16, 2022
Details : The approval of ADLARITY (donepezil transdermal system) reinforces the value of Corium's innovative CORPLEX technology, our CNS expertise, and our mission to deliver solutions that transform care for the Alzheimer's community and others impacted by CNS d...
Product Name : Adlarity
Product Type : Small molecule
Upfront Cash : Not Applicable
March 14, 2022
Details : Donepezil is a current typical treatment that has been widely prescribed for the longest period for Alzheimer’s disease patients in severity ranging from mild to moderate and severe ones among FDA-approved Alzheimer's treatments.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
November 16, 2021
LOOKING FOR A SUPPLIER?
Reset All
